NCCN Guidelines Updated to Include PSMA-PET Imaging

NEXT STORY
Positive Interim Results of CHOICE-01 Study Evaluating Junshi Biosciences and Coherus’ Toripalimab for First Line Treatment of Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer
PREV STORY
Positive Interim Results of CHOICE-01 Study Evaluating Coherus’ and Junshi Biosciences’ Toripalimab for First Line Treatment of Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 01, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology ...

author_avatar
NASDAQ Market News

Immunofluorescence Assay (IFA) Market Size to Reach USD 4.01 Billion in 2028; Growing application of IFA in research and clinical diagnostics is also expected to boost demand for kits and drive revenue growth, Says Reports and Data

author_avatar
NASDAQ Market News

Agenus Presents Results from Two Large Cervical Cancer Trials at ESMO

author_avatar
NASDAQ Market News